Payment overview · 2025
General Payments
$306.78
15 reported records · 11 companies
Healthcare provider profile · identity verified
Jason Watt, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JENSEN BEACH, FL · NPI 1487821641
Verified facts
What the public records show
CMS Open Payments records show Jason Watt, M.D. received $306.78 in general payments during 2025 across 15 reported records.
GlaxoSmithKline, LLC. accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Otezla, Rexulti, Trelegy Ellipta, Yupelri.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Otezla by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ingrezza by this doctor in 2024.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported YUPELRI as an associated drug or biological on 26927 records involving 11152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Yupelri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.58 | 19.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $41.82 | 13.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $37.83 | 12.3% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$33.40 | 10.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.66 | 8.0% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $23.35 | 7.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.10 | 7.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.78 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.78 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.88 | 4.8% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $13.60 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $306.78 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.58 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $41.82 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $37.83 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
| YUPELRI yupelri |
2025 | Yupelri | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | YUPELRI open payments reported associated product |
CMS Open Payments — General Payments 26927 supporting records · 11152 recipient NPIs · example record 1238463489 |
Yupelri · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 775 | 196 |
| Eliquis | Apixaban | 698 | 87 |
| Gabapentin | Gabapentin | 468 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 128 |
| Furosemide | Furosemide | 399 | 107 |
| Trazodone Hcl | Trazodone Hcl | 381 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 365 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 92 |
| Potassium Chloride | Potassium Chloride | 279 | 78 |
| Losartan Potassium | Losartan Potassium | 261 | 77 |
| Metformin Hcl | Metformin Hcl | 226 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 71 |
| Donepezil Hcl | Donepezil Hcl | 210 | 53 |
| Lisinopril | Lisinopril | 210 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 73 |
| Levetiracetam | Levetiracetam | 187 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 54 |
| Omeprazole | Omeprazole | 166 | 64 |
| Sertraline Hcl | Sertraline Hcl | 159 | 45 |
| Buspirone Hcl | Buspirone Hcl | 143 | 35 |
| Meloxicam | Meloxicam | 136 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 34 |
| Mirtazapine | Mirtazapine | 123 | 37 |
| Divalproex Sodium | Divalproex Sodium | 120 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 117 | 30 |
| Baclofen | Baclofen | 115 | 34 |
| Prednisone | Prednisone | 108 | 28 |
| Memantine Hcl | Memantine Hcl | 107 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 49 |
| Montelukast Sodium | Montelukast Sodium | 104 | 28 |
| Carvedilol | Carvedilol | 101 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 28 |
| Simvastatin | Simvastatin | 93 | 25 |
| Tramadol Hcl | Tramadol Hcl | 93 | 35 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 92 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 56 |
| Allopurinol | Allopurinol | 90 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 82 | 13 |
| Alprazolam | Alprazolam | 81 | 19 |
| Midodrine Hcl | Midodrine Hcl | 80 | 25 |
| Glipizide | Glipizide | 79 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | 19 |
| Famotidine | Famotidine | 78 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 35 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 75 | 16 |
| Spironolactone | Spironolactone | 74 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 27 |
| Xarelto | Rivaroxaban | 72 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 21 |
| Nystatin | Nystatin | 71 | 36 |
| Jardiance | Empagliflozin | 69 | suppressed |
| Lactulose | Lactulose | 69 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 14 |
| Latanoprost | Latanoprost | 64 | 17 |
| Cephalexin | Cephalexin | 63 | 22 |
| Insulin Aspart Flexpen | Insulin Aspart | 62 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 17 |
| Azithromycin | Azithromycin | 61 | 44 |
| Bumetanide | Bumetanide | 60 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 13 |
| Novolog Flexpen | Insulin Aspart | 58 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 55 | 27 |
| Finasteride | Finasteride | 53 | 16 |
| Methylprednisolone | Methylprednisolone | 53 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Levofloxacin | Levofloxacin | 51 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 18 |
| Sucralfate | Sucralfate | 50 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 47 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Levemir Flexpen | Insulin Detemir | 43 | suppressed |
| Risperidone | Risperidone | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Pregabalin | Pregabalin | 42 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 37 |
| Celecoxib | Celecoxib | 41 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 11 |
| Ertapenem | Ertapenem Sodium | 38 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 18 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Atenolol | Atenolol | 37 | 11 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 15 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 36 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 36 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 17 |
| Ibuprofen | Ibuprofen | 33 | 12 |
| Methocarbamol | Methocarbamol | 33 | 22 |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 13 |
| Klor-Con 10 | Potassium Chloride | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 12 |
| Temazepam | Temazepam | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 25 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 16 |
| Fluconazole | Fluconazole | 24 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Permethrin | Permethrin | 24 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Procrit | Epoetin Alfa | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 15 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 22 | 15 |
| Linzess | Linaclotide | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 15 |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | 11 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | 12 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Vancomycin | Vancomycin Hcl In 5 % Dextrose | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Briviact | Brivaracetam | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | 13 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl In 5 % Dextrose | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 11 |
| Yupelri | Revefenacin | 15 | suppressed |
| Ampicillin Sodium | Ampicillin Sodium | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Otezla | Apremilast | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 12 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Ivermectin | Ivermectin | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.78 · 15 records | GlaxoSmithKline, LLC. | AUSTEDO XR, CAPLYTA, INGREZZA, MOUNJARO, Natroba, OTEZLA, REPATHA, REXULTI, Secuado, Spinosad, TRELEGY ELLIPTA, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error